secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001933414-24-000050
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys completes Launch-HTN enrollment ahead of schedule; topline data mid-H1 2025
--------------------------------------------------------------------------------

- Enrollment completed ahead of schedule in global Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or resistant hypertension.
- Topline data now anticipated in mid first half of 2025, earlier than originally planned.
- Trial randomized patients to placebo, lorundrostat 50 mg QD, or 50 mg titrated to 100 mg QD; primary endpoint SBP change at 6 weeks.
- Company hosting virtual KOL event on Oct 30 to discuss unmet need and lorundrostat pivotal program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000050/0001933414-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000050/mlys-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer